Open AccessEmpagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial
Author(s) -
G. P. Arutyunov,
Yuri Lopatin,
А.С. Аметов,
F. T. Ageev,
M.B. Antsiferov Antsiferov,
S. Villevalde,
N. G. Vinogradova,
Gagik R. Galstyan,
A. S. Galyavich,
S. R. Gilyarevsky,
М. Г. Глезер,
И. В. Жиров,
M. V. Ilyin,
A. Lebedeva,
S. V. Nedogoda,
В. В. Салухов,
E. I. Tarlovskaya,
S. N. Tereshchenko,
И. В. Фомин,
Yu. Sh. Khalimov,
Н. Р. Хасанов,
Д. В. Черкашин,
S. S. Yakushin
Publication year - 2021
Publication title -
terapevtičeskij arhiv
Language(s) - English
Resource type - Journals
eISSN - 2309-5342
pISSN - 0040-3660
DOI - 10.26442/00403660.2021.12.201281
Subject(s) - empagliflozin , emperor , medicine , heart failure , clinical trial , empa , clinical practice , intensive care medicine , type 2 diabetes mellitus , diabetes mellitus , family medicine , endocrinology , ancient history , chemistry , mineralogy , electron microprobe , history
At an international online expert meeting held on September 16, 2021, the results of the empagliflozin research program EMPA-REG Outcome, EMPEROR-Reduced and EMPEROR-Preserved were reviewed. We analyzed cardiovascular and renal outcomes during the treatment with empagliflozin in patients with chronic heart failure, regardless of the presence of type 2 diabetes mellitus. The positive results of the EMPEROR-Preserved study are updated and their significance for clinical practice is discussed. Several proposals have been adopted that will accelerate the introduction of empagliflozin therapy into practice in patients with heart failure and overcome clinical inertia.